Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mezagitamab in Primary IgA Nephropathy
NCT05174221Phase 1Completed
- Sponsor
- Takeda
- Start
- Aug 2022
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
Phase 1, open-label, single-arm trial of mezagitamab in IgA nephropathy (IgAN), sponsored by Takeda. Primary endpoint: Treatment-emergent Adverse Events at Week 96. Started Aug 2022; status: completed.
02
Drugs
mezagitamab
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT05174221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05174221.